Oticon More vs Otofonix Groove

The Oticon More is a premium behind-the-ear prescription hearing aid that earned an A grade with a SoundScore of 4.6/5 in our lab testing, placing it in the top 22% of the 36 prescription hearing aids we've evaluated. Released in 2021, this device remains competitive and has received HearAdvisor's Expert's Choice Award in both 2023 and 2024. In our testing, the Oticon More demonstrated strong speech clarity performance. Speech in quiet scored 4.0/5, which is 0.73 points above the category average—a notable margin that reflects genuine audibility advantages in everyday conversations. Speech in noise measured 2.7/5, which is above the category average by 0.75 points, though only mixed in absolute terms, meaning challenging listening environments may still require effort. Own-voice comfort scored a solid 3.1/5 (+0.35 vs category average), and music streaming measured 3.0/5 (+0.36 vs category average), both performing above typical prescription aids. Feedback handling scored 3.5/5, which is solid in absolute terms, though below the category average of 4.71/5 by 1.21 points—something to discuss with your hearing care provider. At $4,598, this is a premium-priced device offering iPhone and Android streaming, hands-free calling, and your choice of rechargeable or disposable batteries. The Oticon More is well-suited for those prioritizing speech clarity who want a proven performer from an established manufacturer. Competitors in this price range include the newer Oticon Intent (4.85/5) and Oticon Real (4.75/5), which may be worth comparing during your fitting appointment.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE device ranks 36th out of 36 tested prescription hearing aids, placing it in the bottom tier of its category. In our testing, the Groove demonstrated one clear strength: excellent feedback handling at 5.0/5, scoring 0.29 points above the category average. The device remained stable during our standardized challenge motions with no audible feedback issues. However, speech performance was significantly limited, with both speech in quiet and speech in noise scoring 1.0/5—falling 2.32 and 0.96 points below their respective category averages. Music streaming quality scored 0.0/5, which is 2.64 points below the prescription category average. Own-voice comfort was also low at 0.4/5 in the tuned configuration, 2.35 points below average, suggesting notable occlusion-related concerns. The normalized Initial Score of 2.7/5 and Tuned Score of 2.6/5 indicate that professional fitting adjustments did not improve overall performance. Given its positioning at the bottom of the prescription hearing aid category and the availability of lower-priced alternatives that scored higher in our testing, the Otofonix Groove may be difficult to recommend for most users seeking balanced sound quality across listening situations.